Pharmos, Bausch & Lomb Pharmaceuticals Inc. deal

PARS finalized its previously announced agreement with Bausch & Lomb to market Lotemax, a site-specific ocular steroidal anti-inflammatory agent (see BioCentury May 8). Bausch & Lomb will purchase the active drug from PARS and provide the New York company up to $4 million in cash advances over the next 10 months. ...